Chemed Q3 adj. EPS $5.06 (+4.1%), revenue $539M (+2%); FY21 guidance raised to $19.00-$19.20

CHEMED CORP

2021-Q3 EPS reported $12.06 revenue$1,598,283,000

Repurchased 350,000 shares for $164M; $148M remaining authorization; no long-term debt.
VITAS revenue -5.8% to $317M, ADC -5.3%; Roto-Rooter revenue +15.7% to $221M.
Roto-Rooter adjusted EBITDA margin 29.7% (+266 bps); VITAS margin 19.0% (-146 bps).
Full-year 2021 adjusted EPS guidance raised to $19.00-$19.20 from prior $17.00-$17.50.
Adjusted diluted EPS of $5.06 beats prior-year $4.86; GAAP EPS $4.55.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.